Currently there are 6,000 recognised rare diseases, affecting over 300 million people globally. Despite these staggering numbers, only 5% of
Clinical trials are by design, a scientific experiment, which require highly selective populations in a controlled setting, and with often
Real-world evidence (RWE) is increasingly being used within the regulatory and reimbursement process. RWE studies allow for a clearer understanding
Background The pharmaceutical manufacturer (Sponsor) aimed to study the real-world effectiveness and usage of their medicine in patients with
Background The pharmaceutical manufacturer (Sponsor) wanted to understand the effectiveness of their medication in the real-world. For this
Expanded Access Programs (EAPs), sometimes known as Managed Access Programmes (MAPs), allow pharmaceutical sponsors to offer patients their pre-approval investigational
Get in touch today to speak to one of our expert team and find out how we can help you with your study.
© Copyright Cisiv 2024 | Registered Company Number: 3110147
© Copyright Cisiv
To find out more about the Cisiv technology and how we can help you with your study.
